BioSpace News Archive

Breast lesion or injuries refer to an abnormal change of the breast tissue caused by diseases or injuries.

A Fact.MR survey on self-care medical devices market offers detailed analysis on growth drivers and trends affecting demand in terms of product, end-user and region.

Burning Rock Biotech Limited, a company focused on the application of next generation sequencing technology in the field of precision oncology, announced that it plans to release its unaudited financial results for the second quarter of 2021 before the U.S. market opens on August 31, 2021.

Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets, announced that the UK Medicines and Healthcare Products Regulatory Agency has approved the clinical trial application to initiate first-in-human phase 1 trial of HMBD-001 in patients with advanced cancers.

ElectroPhysiology Frontiers S.p.A., announced that its Board of Directors unanimously appointed Avi Fischer, M.D. as Chief Executive Officer of the company and a member of its Board of Directors.

Mainz, Germany, August 2, 2021 – BioNTech SE will announce its financial results for the second quarter on Monday, August 9th, 2021.

Madrigal Pharmaceuticals, a clinical-stage biopharmaceutical company pursuing novel therapeutics for cardio-metabolic and fatty liver diseases with high unmet medical need, announced that Dr. Robert.

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, announced it will hold a groundbreaking ceremony at the Company’s planned 45,000 square foot clinical scale manufacturing facility in the New Bedford Business Park in Massachusetts on August 3, 2021 at 11:00 a.m. ET.

Advancing its mission to expand access to genetic testing, Myriad Genetics, Inc., a leader in genetic testing and precision medicine, launched a new version of its market-leading MyRisk Hereditary Cancer Test.

FluGen, Inc., a clinical-stage vaccine company transforming vaccine efficacy in infectious respiratory diseases, announced the publication of results from its Phase 2 human challenge study of Bris2007 M2SR, the Company’s investigational, supra-seasonal, live, single-replication, intranasal influenza vaccine.